Paul Hartmann AG (PHH2) - Net Assets
Based on the latest financial reports, Paul Hartmann AG (PHH2) has net assets worth €1.22 Billion EUR (≈ $1.43 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.16 Billion ≈ $2.53 Billion USD) and total liabilities (€938.79 Million ≈ $1.10 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Paul Hartmann AG's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.22 Billion |
| % of Total Assets | 56.56% |
| Annual Growth Rate | 5.44% |
| 5-Year Change | 11.84% |
| 10-Year Change | 49.76% |
| Growth Volatility | 3.69 |
Paul Hartmann AG - Net Assets Trend (2013–2025)
This chart illustrates how Paul Hartmann AG's net assets have evolved over time, based on quarterly financial data. Also explore Paul Hartmann AG assets under control for the complete picture of this company's asset base.
Annual Net Assets for Paul Hartmann AG (2013–2025)
The table below shows the annual net assets of Paul Hartmann AG from 2013 to 2025. For live valuation and market cap data, see market value of Paul Hartmann AG.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.22 Billion ≈ $1.43 Billion |
+2.20% |
| 2024-12-31 | €1.20 Billion ≈ $1.40 Billion |
+7.22% |
| 2023-12-31 | €1.12 Billion ≈ $1.30 Billion |
-1.16% |
| 2022-12-31 | €1.13 Billion ≈ $1.32 Billion |
+3.26% |
| 2021-12-31 | €1.09 Billion ≈ $1.28 Billion |
+12.29% |
| 2020-12-31 | €973.33 Million ≈ $1.14 Billion |
+4.39% |
| 2019-12-31 | €932.40 Million ≈ $1.09 Billion |
+1.00% |
| 2018-12-31 | €923.15 Million ≈ $1.08 Billion |
+7.99% |
| 2017-12-31 | €854.84 Million ≈ $999.40 Million |
+4.73% |
| 2016-12-31 | €816.21 Million ≈ $954.23 Million |
+7.52% |
| 2015-12-31 | €759.10 Million ≈ $887.47 Million |
+9.96% |
| 2014-12-31 | €690.37 Million ≈ $807.12 Million |
+6.70% |
| 2013-12-31 | €647.04 Million ≈ $756.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Paul Hartmann AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 87.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €61.21 Million | 5.21% |
| Other Components | €1.11 Billion | 94.79% |
| Total Equity | €1.17 Billion | 100.00% |
Paul Hartmann AG Competitors by Market Cap
The table below lists competitors of Paul Hartmann AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiahe Foods Industry Co. Ltd.
SHG:605300
|
$724.77 Million |
|
Zhejiang Wellsun Intelligent Tech
SHE:300882
|
$724.95 Million |
|
Ponsse Oyj 1
HE:PON1V
|
$725.08 Million |
|
Merry Electronics Co Ltd
TW:2439
|
$725.52 Million |
|
Slate Grocery REIT
TO:SGR-UN
|
$724.38 Million |
|
Time Publishing and Media Co Ltd Class A
SHG:600551
|
$724.31 Million |
|
Chongqing QinAn M&E PLC
SHG:603758
|
$724.29 Million |
|
Jiangxi Salt Industry Group Co. Ltd. A
SHG:601065
|
$724.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Paul Hartmann AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,148,549,000 to 1,174,653,000, a change of 26,104,000 (2.3%).
- Net income of 61,213,000 contributed positively to equity growth.
- Dividend payments of 28,414,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €61.21 Million | +5.21% |
| Dividends Paid | €28.41 Million | -2.42% |
| Other Changes | €-6.70 Million | -0.57% |
| Total Change | €- | 2.27% |
Book Value vs Market Value Analysis
This analysis compares Paul Hartmann AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.92x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €230.70 | €212.00 | x |
| 2018-12-31 | €248.81 | €212.00 | x |
| 2019-12-31 | €250.15 | €212.00 | x |
| 2020-12-31 | €261.34 | €212.00 | x |
| 2021-12-31 | €293.69 | €212.00 | x |
| 2022-12-31 | €303.78 | €212.00 | x |
| 2023-12-31 | €299.40 | €212.00 | x |
| 2024-12-31 | €323.38 | €212.00 | x |
| 2025-12-31 | €330.73 | €212.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Paul Hartmann AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.21%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.50%
- • Asset Turnover: 1.13x
- • Equity Multiplier: 1.84x
- Recent ROE (5.21%) is below the historical average (8.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 9.24% | 3.19% | 1.51x | 1.91x | €-4.72 Million |
| 2014 | 11.10% | 3.94% | 1.50x | 1.88x | €7.28 Million |
| 2015 | 10.85% | 4.05% | 1.52x | 1.76x | €6.19 Million |
| 2016 | 10.87% | 4.28% | 1.49x | 1.70x | €6.80 Million |
| 2017 | 10.76% | 4.28% | 1.44x | 1.75x | €6.21 Million |
| 2018 | 8.94% | 3.73% | 1.41x | 1.70x | €-9.36 Million |
| 2019 | 6.56% | 2.66% | 1.36x | 1.81x | €-30.58 Million |
| 2020 | 11.47% | 4.38% | 1.41x | 1.86x | €13.66 Million |
| 2021 | 9.08% | 4.11% | 1.26x | 1.75x | €-9.64 Million |
| 2022 | 3.35% | 1.56% | 1.15x | 1.86x | €-71.75 Million |
| 2023 | 2.67% | 1.21% | 1.18x | 1.87x | €-77.92 Million |
| 2024 | 9.44% | 4.50% | 1.15x | 1.83x | €-6.40 Million |
| 2025 | 5.21% | 2.50% | 1.13x | 1.84x | €-56.25 Million |
Industry Comparison
This section compares Paul Hartmann AG's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $6,199,585,877
- Average return on equity (ROE) among peers: -8.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Paul Hartmann AG (PHH2) | €1.22 Billion | 9.24% | 0.77x | $724.56 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $419.42 Million | 24.02% | 0.76x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.67 Billion | 11.61% | 1.89x | $15.47 Billion |
| MEDIMI AB AK (79T) | $13.75 Million | -103.63% | 0.50x | $365.27K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-938.43K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $894.98 Million |
| Carl Zeiss Meditec AG (AFX) | $2.06 Billion | 8.69% | 0.65x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.17 Billion | 13.36% | 0.40x | $2.14 Billion |
| Bio-gate AG (BIG1) | $1.79 Million | -90.74% | 1.21x | $7.08 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $17.94 Billion | 28.16% | 1.68x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $35.88 Billion | 4.04% | 0.66x | $78.07 Billion |
About Paul Hartmann AG
Paul Hartmann AG manufactures and sells medical and care products in Germany, the rest of Europe, the Middle East, Africa, Asia and Pacific region, and the Americas. The company operates through three segments: Wound Care, Incontinence Management, and Infection Management. It offers absorbent underwear, incontinence pads and pants, and fixation pants; medical skincare products; wound management p… Read more